PER 0.00% 10.5¢ percheron therapeutics limited

Sarepta FDA Hearing, page-55

  1. 3,174 Posts.
    lightbulb Created with Sketch. 566
    using Sarepta's revenue as an income guide, with just 30% of the dmd population, earning 1B USD a year, one could assume 90% would = $3B USD or $4B AUD in the USA alone. Double this for the EU and there's $8B AUD per year. That sounds crazy... but it IS happening right now.

    $8B x 20 (about current SRPT ratio) = $160B or $160 dollars a share. hmmm what could I buy with that kind of money.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.